Products

HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.
ABMD Software
HeartLung Corporation
Endocrinology & Metabolic AI
ABMD Software by HeartLung Corporation is an AI-powered, cloud-based tool for opportunistic osteoporosis screening, assessing bone mineral density from existing CT scans without additional radiation.
AI-CVD
HeartLung AI
Cardiology AI
AI-CVD® is an FDA-cleared, AI-powered quantitative imaging platform from HeartLung Corporation that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.

See all 3 products →

About HeartLung

HeartLung.AI is a health-tech company focused on leveraging artificial intelligence for the early detection and prevention of cardiovascular disease and lung cancer. Their mission is to shift healthcare from late-stage disease treatment to earlier identification and prevention by unlocking clinically actionable information embedded within routine medical imaging.

The company has developed several FDA-cleared and breakthrough-designated AI platforms. HeartLung’s AI-CVD platform allows for automated extraction of measurements from CT scans for comprehensive cardiovascular risk assessment. This includes AutoBMD, an FDA 510(k) cleared, DEXA-equivalent, CT-based opportunistic osteoporosis screening tool applicable to millions of CT scans annually. They also have AutoChamber AI, which received FDA “Breakthrough Designation” and marketing authorization for detecting enlarged cardiac chambers and left ventricular hypertrophy in non-contrast chest CT scans, often invisible to the human eye. HeartLung is also awaiting approval for AutoCAC (Automated Coronary Calcium Scoring) and other AI modules focusing on chest CT scans.

HeartLung’s AI solutions are designed to integrate into existing radiology workflows, providing automated, quantitative outputs that can help identify diseases like heart disease, lung cancer, COPD, osteoporosis, and fatty liver disease years before symptoms appear. Their technology aims to provide fast, actionable data for multiple diseases from a single chest CT scan, supporting population health and value-based care.

Focus Areas

cardiovascular disease lung cancer emphysema/COPD osteoporosis myosteatosis fatty liver disease early disease detection preventive imaging AI-powered diagnostics

Business Intelligence

Technologycloud-based, AI-powered quantitative imaging platform that integrates with existing PACS systems and delivers DICOMized PDF reports

What Physicians Need to Know

Early Detection of Cardiovascular Disease (CVD)
HeartLung specializes in the AI-powered early detection of various cardiovascular conditions, including coronary heart disease, heart failure, atrial fibrillation, and stroke. Their AI-CVD® platform extracts quantitative imaging biomarkers from routine CT scans to identify risks that might otherwise be missed.
Lung Cancer & Pulmonary Conditions
The company offers AI-driven solutions for the early detection of lung cancer and pulmonary conditions like emphysema/COPD by analyzing existing CT scans.
Osteoporosis Screening
HeartLung provides AutoBMD™, an FDA-cleared AI-powered bone density screening solution that utilizes routine CT scans (including chest and abdomen) to detect osteoporosis, offering a DEXA-equivalent assessment.
Metabolic and Cardiometabolic Conditions
Their technology also enables the opportunistic detection of fatty liver disease and myosteatosis (fat infiltration into skeletal muscle), which are linked to metabolic syndrome, diabetes, and increased cardiovascular risk.
AI-Powered Quantitative Imaging
HeartLung's core technology, AI-CVD®, is an FDA-cleared platform that automatically extracts quantitative imaging measurements from eligible cardiac and chest CT scans. This includes coronary artery calcium (CAC) scoring (including Agatston-2.0 AI-enabled New CalciumScore), aortic and valvular calcification, cardiac chamber size, epicardial and visceral fat, liver density, lung density, bone mineral density, and muscle-fat composition.
FDA Breakthrough Device Designation
HeartLung received FDA Breakthrough Device Designation for AutoChamber™, an AI tool that detects enlarged cardiac chambers and left ventricular hypertrophy from non-contrast chest CT scans, which are often invisible to the human eye.
Opportunistic Screening
A key differentiator is their focus on 'opportunistic screening,' leveraging existing CT scans performed for other reasons to identify multiple life-threatening conditions without additional imaging, radiation, contrast, or workflow disruption.
Physician Tip

HeartLung's AI solutions provide physicians with comprehensive, actionable insights from routine CT scans, enabling earlier detection, improved risk stratification, and timely preventive interventions for a wide range of cardiovascular, pulmonary, metabolic, and skeletal conditions. The AI-generated reports offer quantitative measurements that can enhance diagnostic accuracy and support clinical decision-making, potentially leading to better patient outcomes and reduced late-stage disease. The seamless integration with existing PACS and rapid AI turnaround within minutes allows for easy adoption without significant workflow changes.

HeartLung's services are designed for simple and easy workflow integration. Providers can set up an account quickly and install a HeartLung Gateway to automatically send scans to their cloud-based AI platform. AI-generated DICOMized PDF reports are then sent directly back to the facility's PACS. Referring physicians can also manually upload CT scans and receive instant AI-generated reports.

Products by HeartLung

3 products in the directory

HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.
ABMD Software
HeartLung Corporation
Endocrinology & Metabolic AI
ABMD Software by HeartLung Corporation is an AI-powered, cloud-based tool for opportunistic osteoporosis screening, assessing bone mineral density from existing CT scans without additional radiation.
AI-CVD
HeartLung AI
Cardiology AI
AI-CVD® is an FDA-cleared, AI-powered quantitative imaging platform from HeartLung Corporation that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.

What the Web Says

HeartLung (also referred to as HeartLung Technologies or HeartLung.AI) is a health-tech company that develops AI-enabled solutions for the early detection of heart disease, lung cancer, osteoporosis, fatty liver disease, and other conditions using standard CT scans. Their flagship product, AI-CVD, is an FDA-cleared AI-powered quantitative imaging platform that can extract clinically relevant cardiovascular and systemic measurements from existing CT scans without additional imaging or workflow disruption. Employer reviews for "Heart Lung" (which may or may not be the same entity as HeartLung Technologies) are limited but generally positive, highlighting good learning opportunities and supportive staff.

Overall: Positive

Strengths

  • AI-enabled solutions for early detection of various diseases using existing CT scans.
  • FDA-cleared platform (AI-CVD) for comprehensive opportunistic screening.
  • Automated extraction of clinically relevant measurements without additional radiation or contrast.
  • Potential to identify patients at increased risk for earlier intervention and improved outcomes.
  • Good learning experience and opportunities for advancement (based on limited employer reviews).
  • Supportive staff and management (based on limited employer reviews).

Limitations

  • Limited number of publicly available product reviews from major platforms like G2, Capterra, and Glassdoor.
  • Employer reviews are scarce and may not be directly tied to HeartLung Technologies.
  • Some Reddit discussions about AI in healthcare show general skepticism or concerns about anthropomorphizing AI.
  • No specific negative product features or company culture issues were found in the available search results.
  • Capterra and G2 show alternatives to HeartLung AI-CVD, but not direct negative reviews of HeartLung itself.
  • The distinction between "Heart Lung" as an employer and "HeartLung Technologies" as a product company is not always clear in search results.

Based on reviews from: Indeed.com, HeartLung.AI, Diagnostic and Interventional Cardiology (DAIC), AuntMinnie, Reddit, G2, The National Law Review

Last updated: 2026-10-23

Videos

News, demos, and interviews about HeartLung.

Loading videos...

Videos load interactively. If none appear, search YouTube for HeartLung →

View all on YouTube

Press & Coverage

AuntMinnie
FDA clears HeartLung's AI-CVD platform
HeartLung received 501(k) clearance from the FDA for its AI-CVD platform, which automates the extraction of cardiovascular and systemic measurements from CT scans.
2026-01
PRWeb
FDA Clears HeartLung's AI-CVD®, Enabling the Broadest Opportunistic Cardiovascular & Multisystem CT Screening Platform
HeartLung Corporation announced FDA clearance of AI-CVD®, its flagship AI-powered quantitative imaging platform, making it the most comprehensive FDA-cleared opportunistic screening platform for CT imaging.
2026-01
EIN Presswire
HeartLung AI Welcomes CMS Coverage for AI-Enabled Opportunistic Coronary Artery Calcium (CAC) Detection on Chest CT
HeartLung AI's AI-CVD platform, including AI-CAC and AutoCAC, aligns with new CMS coverage for algorithmic analysis of coronary artery calcium and/or aortic valve calcification from chest CT.
2026-04
EIN Presswire
HeartLung.AI Emerges as a Leading Innovator in Cardiology with 10 Accepted ESC.26 Abstracts
HeartLung.AI announced 10 scientific abstracts accepted for presentation at ESC Congress 2026, showcasing its leadership in AI-enabled cardiovascular imaging and preventive cardiology.
2026-05
Cardiovascular Business
FDA Clears AI Tool That Flags Signs of Heart Disease in Chest CT Scans
HeartLung Technologies received 510(k) clearance from the FDA for AutoChamber, software that assesses chest CT scans for signs of coronary artery disease and other heart conditions.
2024-11
EIN Presswire
HeartLung Technologies Receives FDA “Breakthrough” Designation and Marketing Authorization for AutoChamber™
HeartLung Technologies secured "Breakthrough Medical Device" designation and marketing authorization from the FDA for AutoChamber™, an AI tool for opportunistic detection of enlarged heart chambers on non-contrast CT scans.
2024-10
DAIC
HeartLung.AI Tool Receives 'FDA Breakthrough' AI Clearance | DAIC
AutoChamber, HeartLung's AI tool, received FDA Breakthrough Device designation, allowing for the detection of enlarged cardiac chambers and left ventricular hypertrophy from various chest CT scans.
2024-10
EIN Presswire
HeartLung.AI Expands Preventive Imaging AI on Precision Imaging Network, part of Microsoft for Healthcare
HeartLung.AI announced that its AutoChamber™ and AutoBMD™ AI services will be available through Precision Imaging Network, part of Microsoft for Healthcare, to accelerate the adoption of advanced imaging algorithms.
2026-02

Frequently Asked Questions

HeartLung's technology focuses on early detection of a range of conditions including heart disease, lung cancer, osteoporosis, fatty liver disease, emphysema/COPD, myosteatosis, cardiovascular disease, stroke, atrial fibrillation, and heart failure. Our primary product offerings include advanced imaging analysis software and AI-powered diagnostic tools designed to integrate seamlessly with existing clinical workflows, providing actionable insights for physicians.
HeartLung prioritizes compliance with all relevant medical regulations and data privacy standards, including HIPAA and GDPR. Our solutions are developed with a privacy-by-design approach, incorporating robust encryption, access controls, and audit trails to protect patient data. We also undergo regular third-party audits and maintain comprehensive documentation to demonstrate our commitment to regulatory adherence.
HeartLung offers flexible pricing structures tailored to the needs of different practice sizes and hospital systems. We provide various tiers and subscription models, which can include per-study fees, annual licenses, or enterprise-wide agreements. Our goal is to ensure our advanced diagnostic tools are accessible and cost-effective for a wide range of healthcare providers.
HeartLung provides comprehensive technical support and clinical training to ensure effective implementation and utilization of our platforms. This includes dedicated account managers, 24/7 technical assistance, on-site training sessions, and a library of educational resources. We are committed to empowering healthcare professionals to maximize the benefits of our diagnostic solutions.
Yes, HeartLung actively engages in strategic partnerships with other healthcare technology companies, leading research institutions, and pharmaceutical companies. These collaborations allow us to integrate our solutions with broader healthcare ecosystems, enhance our research and development capabilities, and ultimately bring more innovative and comprehensive diagnostic tools to our users.
HeartLung is committed to long-term stability and continuous innovation in the healthcare AI space. Our vision includes ongoing investment in research and development to expand our diagnostic capabilities and address emerging healthcare challenges. We aim to maintain a strong market presence by consistently delivering cutting-edge solutions that improve patient outcomes and support healthcare providers.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]

The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]

PHQ Screeners is a free, open-access resource maintained by Pfizer, providing a comprehensive suite of Patient Health Questionnaire (PHQ) and Generalized Anxiety Disorder (GAD-7) screening instruments. These tools were developed by Drs. Robert L. Spitzer, Janet B.W. Williams, and Kurt Kroenke with an educational grant from Pfizer, and are widely utilized in primary care and […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.